Sökning: WFRF:(Bratt Ola)
> Johansson L >
CHEK2*1100delC is n...
CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden
-
Wagenius, M (författare)
-
- Borg, Åke (författare)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Johansson, L (författare)
-
visa fler...
-
- Giwercman, Aleksander (författare)
- Lund University,Lunds universitet,Reproduktionsmedicin, Malmö,Forskargrupper vid Lunds universitet,Reproductive medicine, Malmö,Lund University Research Groups
-
- Bratt, Ola (författare)
- Lund University,Lunds universitet,Urologi,Forskargrupper vid Lunds universitet,Urology,Lund University Research Groups
-
visa färre...
-
(creator_code:org_t)
- 2009-07-09
- 2006
- Engelska.
-
Ingår i: Scandinavian Journal of Urology and Nephrology. - : Informa UK Limited. - 0036-5599 .- 1651-2065. ; 40:1, s. 23-25
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective. CHEK2* 1100delC is a frame-shifting germ-line mutation which abolishes the function of cell-cycle-checkpoint kinase 2 (chk2) and hence impairs the cells' response to DNA damage. This variant occurs in approximate to 1% of the general Western population but has been reported to be more common among patients with breast and prostate cancer. The aim of this study was to investigate the significance of CHEK2* 1100delC as a possible high-risk gene for hereditary prostate cancer in the population of southern Sweden. Material and methods. We screened for the CHEK2* 1100delC variant in 419 men diagnosed with prostate cancer in southern Sweden, 145 of whom were sporadic cases that were divided into two subgroups depending on whether they were diagnosed before ( n = 64) or after ( n = 81) the age of 55 years. A further 126 men were classified as familial prostate cancer cases and 148 as hereditary prostate cancer cases. The control group consisted of 305 military conscripts aged approximate to 18 years ( range 18 - 21 years). Results. The CHEK2* 1100delC variant was found in 1.2% of the cases ( sporadic: 0.7%; familial: 1.6%; hereditary: 1.4%) and in 1.0% of the controls. Conclusion. The CHEK2 1100delC mutation is not a clinically important high-risk gene for hereditary prostate cancer susceptibility in the population of southern Sweden.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- cell-cycle-checkpoint kinase 2
- genetics
- germ-line mutation
- risk factors
- prostatic neoplasms
- CHEK2
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas